Net Loss per Common Share |
6 Months Ended | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | ||||||||||||||||||||||||||||||||||||
| Net Loss per Common Share | ||||||||||||||||||||||||||||||||||||
| Net Loss per Common Share | Note 9 – Net Loss per Common Share The Company calculates net loss per common stock in accordance with ASC Topic 260, Earnings Per Share (“ASC 260”). Basic and diluted net loss per common stock was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Under ASC 260, shares issuable for little or no cash consideration are considered outstanding common stock and included in the computation of basic net loss per share. As such, for the three and six months ended June 30, 2026 and 2025, the Company included its outstanding pre-funded warrants in its computation of net loss per share. The pre-funded warrants are each exercisable into one share of common stock at an exercise price of $0.001 per share. The following potentially dilutive securities have not been included in the computation of diluted net loss per share for the three and six months ended June 30, 2026 and 2025, as the result would be anti-dilutive:
|